FGF23 and hypophosphatemia: One known side effect of intravenous iron treatment is hypophosphatemia, particularly with ferric carboxymaltose, which has been associated with increased fibroblast growth factor 23 (FGF23) production that suppresses renal phosphate reabsorption [15,16].